Artificial intelligence has undoubtedly been the hottest investing topic on Wall Street this year. Led by such products as Wegovy, manufactured by Danish pharmaceutical giant Novo Nordisk (NYSE: NVO), the area of obesity care is garnering substantial attention. One of Novo Nordisk's strengths is its focus on diabetes and obesity care.
Both of these stocks have been big winners this year. But one could be better positioned to extend that winning streak over the next decade.
Novo Nordisk stock has been a red-hot buy this year -- can it continue that trend through this decade?